Pharma Integrates 2024

Connect with Pharma and Healthcare leaders pioneering change

12th November 2024


  • TRACK 1: Big Health Issues & Enablers
  • TRACK 2: Technology

Sponsors Include:

Pioneer Group CPI Emerson Automation Solutions Mills & Reeve UKRI SCIENCE & TECHNOLOGY FACILITIES COUNCIL Team Consulting Quotient Sciences IDBS


08:30 - 09:30
Registration & Networking
09:30 - 09:40
Welcome & Opening Remarks:
Miranda Knaggs

Miranda Knaggs

Pioneer Group

09:40 - 09:50
Keynote Address:
Susan Rienow

Susan Rienow

Pfizer, ABPI

09:50 - 10:15
Fireside Chat 1: The UK as a Life Sciences superpower.
What next? The UK has world leading strengths in academic research and early stages of company development and yet has struggled to grow new companies to scale. The Life Sciences industrial strategy, sector deals, regulatory strategies and financing initiatives have provided a framework for growth but how to execute strategy in the light of tightening in healthcare budgets impacting access and pricing? Will the new governments in the UK and US help or hinder growth?
Susan Rienow

Susan Rienow

Pfizer, ABPI

Lord James O’Shaughnessy

Lord James O’Shaughnessy

Newmarket Strategy

Roz Bekker

Roz Bekker

Johnson & Johnson Innovative Medicine

10:20 - 10:45
Fireside Chat 2
10:45 - 11:15
Networking Coffee Break

Big Health Issues & Enablers

How to tackle some of the biggest health challenges, such as obesity and cancer. How to enable a better Industry, through empowering the patient and navigating the commercial and regulatory environment


How we can use technology to improve health outcomes, improve sustainability and create robust supply chains

11:15 - 12:00

Let’s get digital

‘Artificial intelligence’, ‘data’ and ‘digital’ are still very much the buzz words of innovation. From accelerating drug discovery, to improving diagnosis, right through collecting health data through apps, how are these new tools transforming healthcare?

Facilitated by

Phil Carvil

UKRI Science and Technology Facilities Council


  • Richard Vellacott | BiologIC Technologies
  • Philip Cruz | Moderna
  • Nicola Clear | Pfizer UK
  • James Fry | Mills & Reeve
  • Jenny Barnett | Monument Therapeutics

11:15 - 12:00

We’ve got the green light, are we ready to go?

If we’re to hit the UK target of Net Zero by 2050, all sectors must take action now. As an industry built on innovation, how can the pharma sector lead this change?


  • Laura Kelly | PwC

Headline Sponsor:

12:05 - 12:50

 The rapid adoption of GLP-1’s

The rapid adoption of GLP-1’s have made this class of drugs a blockbuster. With indications from diabetes, obesity, cardiovascular and dementias, these drugs offer great promise to patients and healthcare systems. There are current supply chain shortages and around 150 new GLP-1 projects have been initiated.

– how will GLP-1’s impact treatment of chronic conditions?

– how will the rest of the healthcare system need to adapt [eg mental health support, resistance training and gyms to help manage potential side effects?]

– how will supply chains need to adapt to the massive demand for the current injectable products and further oral therapies. How will the regulatory manage non prescribed use?


  • Hakim Yadi OBE | Closed Loop Medicine

12:05 - 12:50

The three Cs – CDMO, CRO and Change

Strategic partnering with CDMOs and CROs is changing. With a rise in equal partnership models, ‘one-stop shop’ solutions, and collaborative risk management, what is the future of partnering?


  • Vineeta Tripathi | Vitarka Therapeutics

12:50 - 13:50

Networking Lunch

Gold and Silver Sponsors:

14:15 - 15:00

Patients are a virtue

Patients are taking an increasingly proactive role in the development of new treatments. With an increase in patient and public involvement across research, trials and government initiatives, how are we ensuring we design treatments for the people who need them?


  • Sheuli Porkess | Precisia C2-Ai
  • Suzanne Dilly | ValiRx PLC

14:15 - 15:00

Next Generation Digital Technology for Pharma R&D and Manufacturing

The panel will explore what the next generation of digital technology will look and feel like from users’ perspective and will touch on the following questions: Will R&D and manufacturing business processes become more autonomous? How will digital technology and automation technologies come together? Will the patient notice anything different about their medicines?

Facilitated by

Mark Buswell

NGT BioPharma Consultants


  • Siping “Spin” Wang | TetraScience
  • Elena Bonfiglioli | Microsoft

15:05 - 15:50

How can pharma supply chains and partnerships respond to the dynamics of the pharmaceutical market?

Speed of development is increasing and demand forecasts becoming more uncertain due to pricing, market access and competitive behaviour. Governments have been on-shoring and nationalising supply chains and shortages of key drugs remain. How do we optimise manufacturing networks to be nimble and fit for the future? What can we learn from supply chains in other industries to help manage uncertainty and innovation? (semiconductors, aerospace, automotive)


  • Jagjit Singh Srai | University of Cambridge
  • David Harrison | UCB
  • Fozia Saleem | Magnitude Biosciences

15:05 - 15:50

AI beyond drug discovery

McKinsey estimate generative AI to produce $60-100bn in annual value across the harm a value chain. $15-28bn is estimated in drug discovery and we have seen the greatest adoption in this area. A further $38-67bn value is estimated across the rest of the value chain

– how will AI impact clinical development, manufacturing, commercial and medical affairs?

– what regulatory framework do we need to support the effective application of AI? What are the risks and opportunities?

– how do we organise for success?


  • Debra Leeves | Vertual
  • James Duboff | Genomics England

More sessions to follow

16:00 - 17:00

Networking Drinks Reception

Bronze Sponsors:


Victoria House, London

Victoria House, London

Pharma Integrates  2024 Venue: Victoria House

Victoria House, located in the heart of Bloomsbury, London, is a Grade II listed venue with state-of-the-art laboratories available for rent, designed to support scientific research and innovation. The laboratories are fully equipped with advanced technology and facilities, making them ideal for startups, established companies, and research institutions. In addition to labs, Victoria House also features flexible event spaces, advanced AV technology, and professional on-site support.

As part of the Pioneer Group, Victoria House is connected to Europe’s largest collective of scientists, technologists, and entrepreneurs. This dynamic environment supports collaboration with universities, high-growth enterprises, large corporates, healthcare providers, and local government. Pioneer Group offers a range of programmes, including Pre-Accelerator Workshops, Accelerator Programmes, and Launch support, to help businesses grow and innovate. Companies also benefit from expert networks, investment opportunities, and tailored events that foster a unique culture.


Victoria House

Bloomsbury Square, London WC1B 4DA, United Kingdom

Please click here to find us.

More Details

Proudly Sponsored By